Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 6/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695315 | 0.88 | MAOA (0.43) | NOTUMKDM4EALDH1A1CES1HTR2A | |
| SCHEMBL31170780 | 0.88 | MAOA (0.43) | NOTUMKDM4EALDH1A1CES1HTR2A | |
| SCHEMBL5846723 | 0.88 | PARP1 (0.39) | NOTUMCES1HTR2AHTR2CHTR2B | |
| SCHEMBL9274349 | 0.79 | NOTUM (0.47) | NOTUMKDM4EALDH1A1HPGDHTR2A | |
| SCHEMBL18094360 | 0.79 | HTR2A (0.42) | NOTUMKDM4EALDH1A1HPGDHTR2A | |
| SCHEMBL30667056 | 0.79 | NOTUM (0.47) | NOTUMKDM4EALDH1A1HPGDHTR2A | |
| SCHEMBL14021484 | 0.79 | KDM4E (0.41) | NOTUMKDM4EALDH1A1HPGDCASP1 | |
| SCHEMBL11663902 | 0.79 | KDM4E (0.41) | KDM4EALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL22102587 | 0.79 | KDM4E (0.41) | KDM4EALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL28972015 | 0.79 | HPGD (0.41) | KDM4EALDH1A1HPGDCASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-0662971-B1 | 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM | RHONE POULENC RORER SA (FR) | 1998-05-13 | — | — | EP | disclosed |
| US-5677306-A | ANTAGONIZING ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR, USEFUL FOR TREATING ALL ISCHEMIAS | RHONE-POULENC RORER S.A. (FR) | 1997-10-14 | — | — | US | disclosed |
| EP-0662971-A1 | DERIVATIVES OF 5H,10H-IMIDAZO 1,2-a]INDENO 1,2-e]PYRAZINE-4-ONE, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007893-A1 | DERIVATIVES OF 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1994-04-14 | — | — | WO | disclosed |
| EP-0001002-B1 | INDANAMINES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1981-08-12 | — | — | EP | disclosed |
| US-4128666-A | PHENYLETHANOLAMINE N-METHYL-TRANSFERASE INHIBITORS | SMITHKLINE CORPORATION (US) | 1978-12-05 | — | — | US | disclosed |
| US-4096173-A | Chlorinated 1-aminoindane N-methyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | NOTUM 3216/4885KDM4E 2811/4885ALDH1A1 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.